Over the past several years, Glucagon-like peptide-1 receptor agonists (GLP-1s) have revolutionized the field of obesity ...

The selective D1/D5 agonist significantly improved Parkinson’s disease motor symptoms, with low rates of somnolence and ...

A study using positron emission tomography (PET) imaging has found that patients with schizophrenia had significantly lower ...

A new study uses a novel PET radiotracer to uncover widespread M1 receptor deficits in living schizophrenia patients.

A groundbreaking study using positron emission tomography (PET) imaging has found that patients with schizophrenia had ...

Protecting your mental health isn't about chasing the next high, it's about building a steady baseline. Here is your ...

New Canadian data suggest an explanation for long COVID symptoms such as fatigue, lack of motivation, slowed movement, and ...

A real-time imaging study shows neutrophils communicate using catecholamines, much like neurons. This signaling helps control inflammation and links immune responses with blood clotting.

Eyes twitching, a metallic taste in your mouth and peristent fatigue are just a few of the warning signals to pay attention ...

Add Yahoo as a preferred source to see more of our stories on Google. In the corporate world, we spend millions training leaders on strategic execution, yet we rarely address the hidden psychological ...

GLP-1 drugs show promise for more than weight loss. They also cut substance abuse and are changing how we think about the brain’s reward system.

Different receptors respond to different neurotransmitters or hormones, such as adrenaline involved in the fight-or-flight response, or dopamine linked to reward and motivation. Both the receptors ...